Retatrutide (LY-3437943) is a synthetic 39-residue triple agonist designed to activate the GLP-1, GIP, and glucagon (GCGR) receptors with a single molecular backbone. As the first widely-studied reference peptide combining all three incretin and energy-balance pathways, it is a primary tool compound for next-generation metabolic peptide investigations. Supplied as a sterile lyophilized powder for in-vitro and pre-clinical use only.
Retatrutide (LY-3437943) is a synthetic 39-residue triple agonist designed to activate the GLP-1, GIP, and glucagon (GCGR) receptors with a single molecular backbone. As the first widely-studied reference peptide combining all three incretin and energy-balance pathways, it is a primary tool compound for next-generation metabolic peptide investigations. Supplied as a sterile lyophilized powder for in-vitro and pre-clinical use only.
| Size | 10mg × 1 vial, 20mg × 1 vial, 60mg × 1 vial, 40mg × 1 vial |
|---|
Reviews
There are no reviews yet.